Progression Of ETS2101 In Brain Cancer
When trials are done in the name of brain cancer, it's clear that some will be noticed more than others. Very rarely have I ever tuned into a story of this nature to learn that the process is only going to take a day's time. This is a process that calls for attention to detail, so how much detail can be picked up on in such a limited amount of time, you may wonder? It's good to see that certain procedures are set in place, which is the case for the ETS2101 trial.
According to the Wall Street Journal, the ETS2101 trial is one which includes a number of patients, each of them possessing a form of primary or secondary brain cancer. It was done in order to see the effect of ETS2101 and whether or not it is going to be for the best in the long term. As you can imagine, every patient was given a certain dosage so that it can be examined how their bodies take to it. It's been said that this study will continue on through 2014 and I think that organizations such as Voices against Brain Cancer should make note of it.
For those who are unfamiliar with ETS2101, it should be noted that this field is not the only one it's been utilized in. The article said that, in the past, it has been used in order to help patients with cases of trauma. However, with pharmacology set in place, it's been learned that it can help patients with cancer as well. With two ongoing studies being seen - one with patients with primary cancer and the other with patients impacted by secondary cancer - a great deal of dedication has been seen.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
According to the Wall Street Journal, the ETS2101 trial is one which includes a number of patients, each of them possessing a form of primary or secondary brain cancer. It was done in order to see the effect of ETS2101 and whether or not it is going to be for the best in the long term. As you can imagine, every patient was given a certain dosage so that it can be examined how their bodies take to it. It's been said that this study will continue on through 2014 and I think that organizations such as Voices against Brain Cancer should make note of it.
For those who are unfamiliar with ETS2101, it should be noted that this field is not the only one it's been utilized in. The article said that, in the past, it has been used in order to help patients with cases of trauma. However, with pharmacology set in place, it's been learned that it can help patients with cancer as well. With two ongoing studies being seen - one with patients with primary cancer and the other with patients impacted by secondary cancer - a great deal of dedication has been seen.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
About the Author:
Contact Voices Against Brain Cancer if you're looking for some more information about glioblastoma and brain cancer awareness.. Unique version for reprint here: Progression Of ETS2101 In Brain Cancer.